In recent years, we have seen rapid growth in the development of adeno-associated virus (AAV)-mediated gene therapy products that target fatal and highly debilitating diseases. Growth is evident in ...

Demand for lentiviral vectors will continue to outstrip supply until the industry has access to more efficient, purpose-built manufacturing and bioprocessing technologies. The warning comes from ...

Lentiviral vectors have emerged as indispensable tools in gene therapy, offering the ability to integrate therapeutic genes into both dividing and non-dividing cells. Their unique capacity to achieve ...

Kite Pharma's viral vector plant in Southern California has been cleared for liftoff, and, with that, the Gilead Sciences company is touting its position as the only cell therapy player able to make ...

Partnership to Bolster Solid Biosciences’ Gene Therapy Pipeline, Including AAV Process Development, Scale Up and cGMP Manufacturing Services Forge will provide an adeno-associated viral (AAV) vector ...

As a lab within the Cooperative Center of Excellence in Hematology (CCEH) at Fred Hutch, the Vector Production core assists investigators with the design, construction, and/or production of viral ...

The global viral vector manufacturing market is projected to expand at a robust CAGR of approximately 20% over the forecast period, supported by multiple transformative forces reshaping the ...

Bristol Myers Squibb’s cancer cell therapy Breyanzi. Johnson & Johnson and AstraZeneca’s recombinant COVID-19 vaccines. Novartis’ gene therapy Zolgensma. All of these, plus many others, are united by ...

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced the successful closing of a Series D financing round ...

BOSTON & SEATTLE & COLUMBUS, Ohio--(BUSINESS WIRE)--GentiBio, Inc., an emerging biotherapeutics company developing best-in-class engineered regulatory T cells programmed to treat autoimmune, ...

North America dominated the viral vector & plasmid DNA manufacturing market with a revenue share in 2024. Asia Pacific is expected to grow at the fastest CAGR in the market during the forecast period.